Subspecialist second reads of cancer biopsy slides for tier-2 hospitals and labs
TL;DR Slidewise is a network of subspecialist pathologists who re-read cancer biopsies for hospitals and labs in smaller cities before treatment starts. Slides or scanned images come in and a signed second-opinion report goes back within days. Referring hospitals and labs pay per case, because a wrong tumour type means the wrong treatment.
India recorded an estimated 14,61,427 new cancer cases in 2022[1], and almost every treatment decision starts with a pathologist's report. When a Kolkata cancer hospital reviewed 700 outside cases in 2021, 17% had a major discordance that could change treatment, such as benign versus malignant. Major errors were highest in blood and lymph cancers at 23%[2].
That's not a rounding error.
For soft-tissue sarcomas the gap is even wider. An AIIMS team found a major discrepancy in 37% of 97 outside diagnoses, and blamed the near absence of sarcoma pathology expertise outside tertiary centres[3]. If you're a patient in a smaller city then you usually get a second look only if you travel to one of those centres.
What it does, in regulatory terms - diagnostic consultation. Every report is signed by a registered pathologist, and the service does not treat patients. Consultations follow the 2020 Telemedicine Practice Guidelines for registered medical practitioners[4]. If AI triage gets added later then check CDSCO's 2026 medical device software guidance first[5].
Here's how it works. A referring lab or oncologist sends stained slides and blocks by courier, or uploads scanned images where a scanner exists. Slidewise routes each case to a pathologist who specialises in that organ system, who orders extra stains through a partner lab if needed and issues a report that says agreement, refinement or a changed diagnosis. Rare cases go to a panel.
The seed wanted to connect patients with global specialists. I've reframed it to India-based subspecialists, with overseas experts only for rare tumours, because cost and turnaround matter more than geography and the referring doctor (not the patient) is the right buyer.
The patient benefits but the referring hospital, oncologist or lab pays, and it can pass the fee on or absorb it to protect its reputation. Insurers and cancer-focused health plans come later. There's no public price list for pathology second opinions in India, so ₹3,000–8,000 per case, depending on stains, is an assumption you'll have to test.
Hub-and-spoke reading already works for other tests in India - one cardiac-tech firm reads ECGs remotely for hospitals, clinics and state health centres[6]. Indian pathologists themselves now argue for hub labs that support peripheral labs[2]. And the DPDP Rules notified in November 2025 make the consent rules for shared patient data clearer[7].
There's no public figure for the second-opinion pathology market in India. Your anchor is 14.6 lakh new cancer cases a year[1]. If even 2% of biopsies from smaller centres were sent for review then that's about 29,000 cases a year (my own arithmetic). The 17% major-discordance rate[2] is the strongest argument your sales team will have.
Tertiary cancer centres review outside slides, but mostly for patients who move their care there[2]. A US startup sells AI and a digital pathology platform to labs and drug companies[8], which is tooling and not a reading service. National lab chains employ specialists, but they serve their own samples first. The gap is a neutral service any small lab or oncologist can send to.
| Difficulty | Moderate (45/100) |
| Starting capital | ₹80 L–1.6 Cr |
| Time to launch | 6–9 months |
Recruiting and keeping subspecialist pathologists is the real job, since there are so few of them. Courier handling, block return and a turnaround of five to seven days need tight operations. Referring pathologists may also take a changed diagnosis badly, so the reports need careful wording.
Regulated. This is diagnostic consultation, so every report is signed by a registered pathologist.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
AI must not make or change a diagnosis here. Every report is signed by a registered pathologist, and any AI that grades tumours needs a CDSCO check first.
Want to work out the AI layer for Slidewise? Talk to Yash →
Here's what can go south -
I think this is a credible business, but only for a pathologist founder with a network of subspecialist peers and a lab partner. If you're a non-clinical founder without that network then I'd pass. Prove two things first - that ten oncologists in two cities will send cases at a set price, and that you can return reports in seven days.
Plan for roughly ₹80 L–1.6 Cr, mostly on pathologist fees, courier operations and scanners. Start with referrers in two cities.
Each pathologist must be a registered medical practitioner under the Telemedicine Practice Guidelines, and patient data falls under the DPDP Act. NABL accreditation is optional but often asked for.
Yes, subspecialist shortages exist in many countries. Medical registration and cross-border health data rules vary, so check locally before you take cases.
The free Slidewise validation kit has the line-by-line capital breakdown, the effort scoring, the telemedicine, lab and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for oncologists and lab owners, and 5 assumptions to test. Download the kit →
Thinking about building Slidewise or something close to it? The make-or-break work is signing subspecialist pathologists and winning referring labs over as allies rather than rivals. If you need a hand with that, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.